We believe CBD should always be effective, safe to consume and easy to get your hands on, and that’s why we’ve made it our mission to revolutionise the European CBD industry. This can only be done from the grassroots up, and while our responsible, sustainable and transparent processes set the benchmark, research is key in powering the industry forward.

At Dragonfly, we put resources back into academic research, liaise with industry experts and support pioneering blockchain data to make exactly that happen.


Prof. Saoirse O’Sullivan

Saoirse brings 15 years of cannabinoid wisdom to the Dragonfly board. Previously serving as Associate Professor at the University of Nottingham, her research is centred in on the endocannabinoid system, with a particular focus on the role it plays in diabetes and obesity. Since 2016, she has been named Young Investigator of the Year by the International Cannabinoid Research Society and acted as a source of expertise for numerous BBC documentaries. A seasoned academic, she will keep us at the cutting edge of new research findings.

Dr. Andy Yates

Andy is a pharmacist armed with a PhD in cannabinoid medical chemistry from the University of Nottingham, his own pharmaceutical consultancy and over 15 years’ experience in the industry. He is also the pharmacy lead for the Centre for Medicinal Cannabis and has a wealth of experience in the realms of academia, biotechnology and peer pharma. Andy will keep Dragonfly updated with the latest cannabinoid research insights, including new theories, papers and data.


The Melabis Project aims to bring Cannabis to the forefront of technological innovation. More specifically, it harnesses big data on our agricultural process to create unique insights into optimum growing environments. Melabis’ end goal is to create a legal cannabis consumption ecosystem that promotes knowledge collation, transparency and accessibility. This means that in the future, you’ll be able to identify exactly which plant your DragonflyCBD extract originated from.

Dragonfly Biosciences is a proud member of the EIHA. Founded in 2005, its primary aim is connecting hemp cultivators in Europe and fostering a dialogue on hemp policy and regulation. The organisation has a rigorous application process and only accepts those cultivators who comply with its exacting standards. We collaborate with other prominent hemp organisations within the Association to work towards a more responsible and sustainable Cannabis industry in Europe.